#United States #New York #Class Action #Faruqi & Faruqi #INOVIO Pharmaceuticals

Legal Action Ahead for Inovio Pharmaceuticals Investors

Inovio Pharmaceuticals, Inc. is currently under legal scrutiny as concerns over its practices have sparked a class action lawsuit. Faruqi & Faruqi, LLP—a prominent national securities law firm—has highlighted a critical date for investors. On April 7, 2026, the deadline will arrive for shareholders to seek lead plaintiff status in the ongoing federal securities class action against Inovio.

Background of the Class Action

The legal investigation initiated by Faruqi & Faruqi focuses on claims that Inovio and its executives potentially violated federal securities laws. Allegations include misleading statements regarding the manufacturing capabilities of Inovio's CELLECTRA device and false representations about the progress of its Biologics License Application (BLA) for INO-3107. This particular product targets recurrent respiratory papillomatosis.

On December 29, 2025, the FDA acknowledged the receipt of Inovio’s BLA for INO-3107 but noted that the submitted information was insufficient for accelerated approval—a significant setback for the company. This revelation led to a sharp decrease in Inovio’s stock price, further complicating the situation for its investors.

The Role of a Lead Plaintiff

The class action lawsuit aims to appoint a lead plaintiff, defined as the individual or entity with the most significant financial stake in the outcome of the lawsuit who can adequately represent the interests of the class members. The law stipulates that if a potential lead plaintiff does not wish to take on this responsibility, they still retain the right to recover damages from the case as an absentee class member.

Investor Rights and Options

Investors who purchased or acquired Inovio securities between October 10, 2023, and December 26, 2025, are strongly encouraged to weigh their legal options. They can directly reach out to James (Josh) Wilson, a partner at Faruqi & Faruqi, for guidance. The firm has been proactive in informing investors about their rights and any potential courses of action they might consider in light of these developments.

Moreover, anyone with pertinent information regarding Inovio's operational conduct, including former employees and other stakeholders, is invited to share their insights with the firm to further bolster the case.

Next Steps for Investors

As the deadline approaches, it is crucial for affected investors to familiarize themselves with the implications of this lawsuit and to act accordingly. The firm has established channels for contact, including direct phone lines for investors wishing to discuss their situations in detail.

In summary, Inovio Pharmaceuticals finds itself at a pivotal moment as it navigates through legal challenges that could have substantial repercussions for its future. With deadlines looming and the potential for severe financial impacts, investors must remain vigilant and informed about their rights and options in the ongoing class action case.